278650.Kq

The company maintains a strong liquidity position, with cash and equivalents amounting to KRW 41,154,584,840, which represents 26.45% of its total assets. Its liquidity FPT (free cash flow to total debt) is not explicitly provided, but the company's current ratio of 1.26 suggests a moderate ability to meet short-term obligations. The price-to-book ratio of 3.54 indicates that the market values the company at a premium to its book value, which may reflect expectations of future growth or intangible assets.

Profitability metrics show a challenging performance, with a negative return on equity (ROE) of -19.7% and a negative return on assets (ROA) of -12.19%. These figures are below the typical expectations for the biotechnology and medical research industry, which often balances high R&D costs with long-term growth potential. The company reported a net loss of KRW 18,961,701,880 and an operating loss of KRW 17,831,931,710, indicating significant operational challenges.

The company's revenue is concentrated in a single business segment, as no segment-specific data is provided in the available financials. There is no indication of geographic diversification in the revenue mix, which could expose the company to regional economic or regulatory risks. The lack of segmental or geographic breakdown limits the ability to assess the company's exposure to different markets or product lines.

The company's growth trajectory appears to be under pressure, with a net loss and negative operating income reported in the latest financial period. While the company generated positive operating cash flow of KRW 3,086,102,180, its free cash flow was negative at KRW -17,596,899,330, indicating that capital expenditures and other cash outflows exceeded operating cash inflows. This suggests that the company may need to rely on external financing or asset sales to fund ongoing operations or expansion.

Risk factors include a low liquidity rating and a negative net income, which could affect the company's ability to meet financial obligations or invest in growth opportunities. The company has a low dilution risk, with no immediate filing-based liquidity or dilution flags detected. However, the negative net income and operating loss may necessitate future equity or debt financing, which could lead to dilution or increased leverage.

There are no recent events or filings mentioned in the provided data that would indicate significant changes in the company's operations or financial position. The absence of recent events or transcripts does not imply stability, but rather a lack of disclosed material developments in the latest available data.